It's official: dramatic share price jumps in response to clinical data have become more common.
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
In terms of private investments, 2020 was the year of the liquid biopsy.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
It takes more than a pandemic to stop medical device companies merging.